Inverse GAS5-SFXN1 Correlation in Triple-Negative Breast Cancer: Insights from Bioinformatics and Tissue Expression Analysis

Sam Daliri, Pourya; Vlizadeh-Otaghsara, Maryam; Paryan, Mahdi; Ahmadizad Firouzjaei, Ali; Mohammadi-Yeganeh, Samira

doi:10.22034/IBJ.30.4.241

Volume 30, Issue 4 (9-2026) IBJ 2026, 30(4): 241-253 | Back to browse issues page

‎ 10.22034/IBJ.30.4.241

PMID: 42806745

Mendeley

Zotero

RefWorks

Sam Daliri P, Vlizadeh-Otaghsara M, Paryan M, Ahmadizad Firouzjaei A, Mohammadi-Yeganeh S. Inverse GAS5-SFXN1 Correlation in Triple-Negative Breast Cancer: Insights from Bioinformatics and Tissue Expression Analysis. IBJ 2026; 30 (4) :241-253
URL: http://ibj.pasteur.ac.ir/article-1-5664-en.html

Inverse GAS5-SFXN1 Correlation in Triple-Negative Breast Cancer: Insights from Bioinformatics and Tissue Expression Analysis

Pourya Sam Daliri

, Maryam Vlizadeh-Otaghsara

, Mahdi Paryan

, Ali Ahmadizad Firouzjaei

, Samira Mohammadi-Yeganeh ^*

Abstract:

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. Given the involvement of long non-coding RNAs, like GAS5, in cancer progression, this study aimed to identify GAS5-associated target genes through breast cancer databases and evaluate the expression levels of GAS5 and SFXN1 (as a potential target) in TNBC tissues.
Methods: After predicting putative GAS5 targets via StarBase, they were validated through TCGA and GEPIA2. RT-qPCR was then performed to examine GAS5 and SFXN1 expression in 18 tumor and 15 adjacent normal samples. Gene expression levels were quantified using the fold-change method, and statistical analyses were performed using linear mixed models, one-sample t-tests, and Spearman’s correlation.
Results: Bioinformatics analyses revealed significant differential expression of SFXN1 in the TCGA and GEPIA2 databases. In the experimental validation phase, the mean Log₂FC values for GAS5 and SFXN1 in tumor samples were 0.235 and -0.450, respectively. Neither gene showed a statistically significant difference between tumor and normal tissues using the t-test (GAS5: p = 0.650; SFXN1: p = 0.458). The linear mixed model also revealed no significant difference for either gene in the same comparison. Spearman’s correlation, however, demonstrated a significant negative correlation between GAS5 and SFXN1 expression (r = -0.479; p = 0.049).
Conclusion: While GAS5 and SFXN1 were not differentially expressed in TNBC tissues, their significant inverse correlation suggests a potential association that may contribute to the molecular networks underlying TNBC pathogenesis. Further functional studies are warranted to clarify this relationship. Any diagnostic or therapeutic implications remain speculative at this stage.

Keywords: GAS5 long non-coding RNA, Long non-coding RNA, Triple negative breast neoplasms, SFXN1 protein

Full-Text [PDF 1623 kb]

Type of Study: Full Length/Original Article | Subject: Related Fields

References

1. Thangavelu L, Moglad E, Gupta G, Menon SV, Gaur A, Sharma S, et al. GAS5 lncRNA: A biomarker and therapeutic target in breast cancer. Pathology-Research and Practice. 2024;260:155424. [DOI:10.1016/j.prp.2024.155424]

2. Wichtowski M, Kołacińska-Wow A, Skrzypek K, Jabłońska E, Płoszka K, Kołat D, et al. Molecular Implications of ADIPOQ, GAS5, GATA4, and YAP1 Methylation in Triple-Negative Breast Cancer Prognosis. International Journal of Molecular Sciences. 2025;26(21):10652. [DOI:10.3390/ijms262110652]

3. Marchina E, Fontana MG, Speziani M, Salvi A, Ricca G, Di Lorenzo D, et al. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management. Oncology reports. 2010;24(6):1661-7. [DOI:10.3892/or_00001031]

4. Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Journal of Clinical Oncology. 2023;41(9):1703-13. [DOI:10.1200/JCO.22.01239]

5. Abeni E, Grossi I, Marchina E, Coniglio A, Incardona P, Cavalli P, et al. DNA methylation variations in familial female and male breast cancer. Oncology Letters. 2021;21(6):468. [DOI:10.3892/ol.2021.12729]

6. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. The Lancet. 2021;397(10286):1750-69. [DOI:10.1016/S0140-6736(20)32381-3]

7. Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nature reviews Molecular cell biology. 2023;24(6):430-47. [DOI:10.1038/s41580-022-00566-8]

8. Gao N, Li Y, Li J, Gao Z, Yang Z, Li Y, et al. Long non-coding RNAs: the regulatory mechanisms, research strategies, and future directions in cancers. Frontiers in oncology. 2020;10:598817. [DOI:10.3389/fonc.2020.598817]

9. Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome biology. 2017;18(1):206. [DOI:10.1186/s13059-017-1348-2]

10. Frankish A, Diekhans M, Jungreis I, Lagarde J, Loveland JE, Mudge JM, et al. GENCODE 2021. Nucleic acids research. 2021;49(D1):D916-D23. [DOI:10.1093/nar/gkaa1087]

11. Hon CC, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJ, Gough J, et al. An atlas of human long non-coding RNAs with accurate 5′ ends. Nature. 2017;543(7644):199-204. [DOI:10.1038/nature21374]

12. Grossi I, Marchina E, De Petro G, Salvi A. The biological role and translational implications of the long non-coding RNA GAS5 in breast cancer. Cancers. 2023;15(13):3318. [DOI:10.3390/cancers15133318]

13. Arshi A, Sharifi FS, Ghahfarokhi MK, Faghih Z, Doosti A, Ostovari S, et al. Expression analysis of MALAT1, GAS5, SRA, and NEAT1 lncRNAs in breast cancer tissues from young women and women over 45 years of age. Molecular therapy Nucleic acids. 2018;12:751-7. [DOI:10.1016/j.omtn.2018.07.014]

14. Pickard MR, Williams GT. Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast cancer research and treatment. 2014;145(2):359-70. [DOI:10.1007/s10549-014-2974-y]

15. Li Y, Guo XB, Wei YH. LncRNA GAS5 affects epithelial-mesenchymal transition and invasion of breast cancer cells by regulating miR-216b. European Review for Medical & Pharmacological Sciences. 2020;24(9).

16. Zhang Z, Zhu Z, Watabe K, Zhang X, Bai C, Xu M, et al. Negative regulation of lncRNA GAS5 by miR-21. Cell Death & Differentiation. 2013;20(11):1558-68. [DOI:10.1038/cdd.2013.110]

17. Li S, Zhou J, Wang Z, Wang P, Gao X, Wang Y. Long noncoding RNA GAS5 suppresses triple negative breast cancer progression through inhibition of proliferation and invasion by competitively binding miR-196a-5p. Biomedicine & Pharmacotherapy. 2018;104:451-7. [DOI:10.1016/j.biopha.2018.05.056]

18. Pei J, Wang B. Notch-1 promotes breast cancer cells proliferation by regulating LncRNA GAS5. International Journal of Clinical and Experimental Medicine. 2015;8(8):14464.

19. Tokgun PE, Tokgun O, Kurt S, Tomatir AG, Akca H. MYC-driven regulation of long non-coding RNA profiles in breast cancer cells. Gene. 2019;714:143955. [DOI:10.1016/j.gene.2019.143955]

20. Smith CM, Steitz JA. Classification of gas5 as a multi-small-nucleolar-RNA (snoRNA) host gene and a member of the 5′-terminal oligopyrimidine gene family reveals common features of snoRNA host genes. Molecular and cellular biology. 1998;18(12):6897-909. [DOI:10.1128/MCB.18.12.6897]

21. Han L, Ma P, Liu S-M, Zhou X. Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects. Tumor Biology. 2016;37(5):6847-54. [DOI:10.1007/s13277-015-4568-7]

22. Toraih EA, El-Wazir A, Ageeli EA, Hussein MH, Eltoukhy MM, Killackey MT, et al. Unleash multifunctional role of long noncoding RNAs biomarker panel in breast cancer: A predictor classification model. Epigenomics. 2020;12(14):1215-37. [DOI:10.2217/epi-2019-0291]

23. Liang W, Lv T, Shi X, Liu H, Zhu Q, Zeng J, et al. Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer. Medicine. 2016;95(37):e4608. [DOI:10.1097/MD.0000000000004608]

24. Li C, Lv Y, Shao C, Chen C, Zhang T, Wei Y, et al. Tumor‐derived exosomal lncRNA GAS5 as a biomarker for early‐stage non‐small‐cell lung cancer diagnosis. Journal of cellular physiology. 2019;234(11):20721-7. [DOI:10.1002/jcp.28678]

25. Badal A, Engelbrecht Z, Cronjé MJ. GAS5 as a therapeutic target in breast cancer through apoptosis induction. Cell Communication and Signaling. 2025;23(1):463. [DOI:10.1186/s12964-025-02457-9]

26. Ma Y, Yu L, Yan W, Qiu L, Zhang J, Jia X. lncRNA GAS5 sensitizes breast cancer cells to ionizing radiation by inhibiting DNA repair. BioMed Research International. 2022;2022(1):1987519. [DOI:10.1155/2022/1987519]

27. Team RC. RA language and environment for statistical computing, R Foundation for Statistical. Computing. 2020.

28. Andriani L, Ling Y-X, Yang SY, Zhao Q, Ma X-Y, Huang M-Y, et al. Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A. Cancer Letters. 2024;597:217008. [DOI:10.1016/j.canlet.2024.217008]

29. Cui J, Duan B, Zhao X, Chen Y, Sun S, Deng W, et al. MBD3 mediates epigenetic regulation on EPAS1 promoter in cancer. Tumor Biology. 2016;37(10):13455-67. [DOI:10.1007/s13277-016-5237-1]

30. Wu X, Li Y, Wang J, Wen X, Marcus MT, Daniels G, et al. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PloS one. 2013;8(10):e77060. [DOI:10.1371/journal.pone.0077060]

31. Kory N, Wyant GA, Prakash G, uit de Bos J, Bottanelli F, Pacold ME, et al. SFXN1 is a mitochondrial serine transporter required for one-carbon metabolism. Science. 2018;362(6416):eaat9528. [DOI:10.1126/science.aat9528]

32. Yuan D, Liu J, Sang W, Li Q. Comprehensive analysis of the role of SFXN family in breast cancer. Open Medicine. 2023;18(1):20230685. [DOI:10.1515/med-2023-0685]

33. Filippova EA, Fridman MV, Burdennyy AM, Loginov VI, Pronina IV, Lukina SS, et al. Long noncoding RNA GAS5 in breast cancer: epigenetic mechanisms and biological functions. International Journal of Molecular Sciences. 2021;22(13):6810. [DOI:10.3390/ijms22136810]

34. Qian Y, Shi L, Luo Z. Long non-coding RNAs in cancer: implications for diagnosis, prognosis, and therapy. Frontiers in medicine. 2020;7:612393. [DOI:10.3389/fmed.2020.612393]

35. Acoba MG, Alpergin ESS, Renuse S, Fernández-del-Río L, Lu Y-W, Khalimonchuk O, et al. The mitochondrial carrier SFXN1 is critical for complex III integrity and cellular metabolism. Cell reports. 2021;34(11). [DOI:10.1016/j.celrep.2021.108869]

36. Tifoun N, De las Heras JM, Guillaume A, Bouleau S, Mignotte B, Le Floch N. Insights into the roles of the sideroflexins/SLC56 family in iron homeostasis and iron-sulfur biogenesis. Biomedicines. 2021;9(2):103. [DOI:10.3390/biomedicines9020103]

37. Zhang L, Wang S, Wang L. Pan‑cancer analysis of oncogene SFXN1 to identify its prognostic and immunological roles in lung adenocarcinoma. Oncol Rep. 2025;53(4). [DOI:10.3892/or.2025.8883]

38. Li Y, Yang W, Liu C, Zhou S, Liu X, Zhang T, et al. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: a potential therapeutic target. International Immunopharmacology. 2024;132:111918. [DOI:10.1016/j.intimp.2024.111918]

39. Liu W, Du Q, Mei T, Wang J, Huang D, Qin T. Comprehensive analysis the prognostic and immune characteristics of mitochondrial transport-related gene SFXN1 in lung adenocarcinoma. BMC cancer. 2024;24(1):94. [DOI:10.1186/s12885-023-11646-z]

40. Zhang Y-H, Liu X-S, Gao Y, Yuan L-L, Huang Z-M, Zhang Y, et al. SFXN1 as a potential diagnostic and prognostic biomarker of LUAD is associated with 18F-FDG metabolic parameters. Lung Cancer. 2024;188:107449. [DOI:10.1016/j.lungcan.2023.107449]

41. Kalantary-Charvadeh A, Morovat S, Aslani S, Ziamajidi N, Emami Razavi A, Abbasalipourkabir R. The role of long non-coding RNA LINC00839 in oral squamous cell carcinoma based on bioinformatics and experimental research. Scientific Reports. 2024;14(1):31817. [DOI:10.1038/s41598-024-82922-6]

42. Goyal A, Fiškin E, Gutschner T, Polycarpou-Schwarz M, Groß M, Neugebauer J, et al. A cautionary tale of sense-antisense gene pairs: independent regulation despite inverse correlation of expression. Nucleic acids research. 2017;45(21):12496-508. [DOI:10.1093/nar/gkx952]

43. Xie X, Sinha S. Quantitative estimates of the regulatory influence of long non-coding RNAs on global gene expression variation using TCGA breast cancer transcriptomic data. PLOS Computational Biology. 2024;20(6):e1012103. [DOI:10.1371/journal.pcbi.1012103]

44. Chiu H-S, Somvanshi S, Chang CT, de Bony de Lavergne EJ, Wei Z, Hsieh C-H, et al. Coordinated regulation by lncRNAs results in tight lncRNA-target couplings. Cell Genomics. 2025;5(8):100927. [DOI:10.1016/j.xgen.2025.100927]

45. Panni S. The Relevance of the Accurate Annotation of Micro and Long Non-Coding RNA Interactions for the Development of Therapies. Genes. 2025;16(3):262. [DOI:10.3390/genes16030262]

46. Fu Y, Liu L, Zhan J, Zhan H, Qiu C. LncRNA GAS5 expression in non-small cell lung cancer tissues and its correlation with Ki67 and EGFR. American Journal of Translational Research. 2021;13(5):4900.

47. Liu X, Jiao T, Wang Y, Su W, Tang Z, Han C. Long non-coding RNA GAS5 acts as a molecular sponge to regulate miR-23a in gastric cancer. Int J Exp Pathol. 2016;9:11412-9.

48. Kanabe BO, Ozaslan M, Aziz SA, Al-Attar MS, Kılıç İH, Khailany RA. Expression patterns of LncRNA-GAS5 and its target APOBEC3C gene through miR-103 in breast cancer patients. Cellular and Molecular Biology. 2021;67(3):5-10. [DOI:10.14715/cmb/2021.67.3.2]

49. Ashouri A, Sayin VI, Van den Eynden J, Singh SX, Papagiannakopoulos T, Larsson E. Pan-cancer transcriptomic analysis associates long non-coding RNAs with key mutational driver events. Nature communications. 2016;7(1):13197. [DOI:10.1038/ncomms13197]

50. Cogill SB, Wang L. Co-expression network analysis of human lncRNAs and cancer genes. Cancer informatics. 2014;13:CIN. S14070. [DOI:10.4137/CIN.S14070]

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb

Iranian

Biomedical Journal